We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » Advisory Panel Votes Against Recommending BMS, AZ Diabetes Drug
Advisory Panel Votes Against Recommending BMS, AZ Diabetes Drug
July 20, 2011
An FDA panel voted 9-6 against recommending approval of Bristol-Myers Squibb (BMS) and AstraZeneca’s diabetes drug dapagliflozin, citing cancer risks and a lack of substantial evidence. Drug Industry Daily
